Bromodomains: Are readers right for epigenetic therapy?

ACS Medicinal Chemistry Letters

Volumn 3, Issue 9, 2012, Pages 691-694

  Conway, Stuart J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMODOMAIN CONTAINING PROTEIN INHIBITOR; I BET151; I BET762; I BETA151; JQ 1; LYSINE; PROTEIN INHIBITOR; RVX 208; UNCLASSIFIED DRUG;

CARCINOMA; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EPIGENETICS; HUMAN; LEUKEMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TREATMENT OUTCOME;

EID: 84866353161     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300221t     Document Type: Review

References (16)

1. Arrowsmith, C. H.; Bountra, C.; Fish, P. V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery Nat. Rev. Drug Discovery 2012, 11, 384-400
2. Kouzarides, T. Acetylation: A regulatory modification to rival phosphorylation? EMBO J. 2000, 19, 1176-1179
3. Filippakopoulos, P.; Knapp, S. The bromodomain interaction module FEBS Lett. 2012, 586, 2692-2704
4. Haynes, S. R.; Dollard, C.; Winston, F.; Beck, S.; Trowsdale, J.; Dawid, I. B. The bromodomain: A conserved sequence found in human, Drosophila and yeast proteins Nucleic Acids Res. 1992, 20, 2603
5. Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites J. Med. Chem. 2012, 10.1021/jm300346w
6. Chung, C.-W.; Tough, D. F. Bromodomains: A new target class for small molecule drug discovery Drug Discovery Today: Ther. Strategies 2012, 10.1016/j.ddstr.2011.12.002
7. Zeng, L.; Li, J.; Muller, M.; Yan, S.; Mujtaba, S.; Pan, C.; Wang, Z.; Zhou, M.-M. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association J. Am. Chem. Soc. 2005, 127, 2376-2377
8. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067-1073
9. Nicodeme, E.; Jeffrey, K. L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.-W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; White, J.; Kirilovsky, J.; Rice, C. M.; Lora, J. M.; Prinjha, R. K.; Lee, K.; Tarakhovsky, A. Suppression of inflammation by a synthetic histone mimic Nature 2010, 468, 1119-1123
10. Hewings, D. S.; Wang, M.; Philpott, M.; Fedorov, O.; Uttarkar, S.; Filippakopoulos, P.; Picaud, S.; Vuppusetty, C.; Marsden, B.; Knapp, S.; Conway, S. J.; Heightman, T. D. 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands J. Med. Chem. 2011, 54, 6761-6770
11. Dawson, M. A.; Prinjha, R. K.; Dittmann, A.; Giotopoulos, G.; Bantscheff, M.; Chan, W.-I.; Robson, S. C.; Chung, C.-W.; Hopf, C.; Savitski, M. M.; Huthmacher, C.; Gudgin, E.; Lugo, D.; Beinke, S.; Chapman, T. D.; Roberts, E. J.; Soden, P. E.; Auger, K. R.; Mirguet, O.; Doehner, K.; Delwel, R.; Burnett, A. K.; Jeffrey, P.; Drewes, G.; Lee, K.; Huntly, B. J. P.; Kouzarides, T. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Nature 2011, 478, 529-533
12. Bamborough, P.; Diallo, H.; Goodacre, J. D.; Gordon, L.; Lewis, A.; Seal, J. T.; Wilson, D. M.; Woodrow, M. D.; Chung, C.-W. Fragment-based discovery of bromodomain inhibitors part 2: Optimization of phenylisoxazole sulfonamides J. Med. Chem. 2012, 55, 587-596
13. Zuber, J.; Shi, J.; Wang, E.; Rappaport, A. R.; Herrmann, H.; Sison, E. A.; Magoon, D.; Qi, J.; Blatt, K.; Wunderlich, M.; Taylor, M. J.; Johns, C.; Chicas, A.; Mulloy, J. C.; Kogan, S. C.; Brown, P.; Valent, P.; Bradner, J. E.; Lowe, S. W.; Vakoc, C. R. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Nature 2011, 478, 524-528
14. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904-917
15. Zhang, G.; Liu, R.; Zhong, Y.; Plotnikov, A. N.; Zhang, W.; Zeng, L.; Rusinova, E.; Gerona-Nevarro, G.; Moshkina, N.; Joshua, J.; Chuang, P. Y.; Ohlmeyer, M.; He, J. C.; Zhou, M.-M. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition J. Biol. Chem. 2012, 10.1074/jbc.M112.359505
16. Seal, J.; Lamotte, Y.; Donche, F.; Bouillot, A.; Mirguet, O.; Gellibert, F.; Nicodeme, E.; Krysa, G.; Kirilovsky, J.; Beinke, S.; McCleary, S.; Rioja, I.; Bamborough, P.; Chung, C.-W.; Gordon, L.; Lewis, T.; Walker, A. L.; Cutler, L.; Lugo, D.; Wilson, D. M.; Witherington, J.; Lee, K.; Prinjha, R. K. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A) Bioorg. Med. Chem. Lett. 2012, 22, 2968-2972